Investors & Media
We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
May 19, 2022Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
May 17, 2022Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 13, 2022Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of lifeOUR VISION:
To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy